Leqembi, an Alzheimer's drug from Biogen and Eisai, isn't a cure for the mind-damaging disease.. But the treatment promises to give patients such as Missie Meeks more time to live their daily ...

Kevin Smith, a resident of Clifton Park, is experiencing the benefits of a recently approved Alzheimer's drug, Leqembi, as he ...

Leqembi has a boxed warning about the risk of ARIA. To learn more, see the introduction of this article. Your doctor will likely order a test to check for ApoE gene status before prescribing Leqembi.

Learn about side effects, uses, cost, and more for Leqembi (lecanemab-irmb), a prescription drug that treats Alzheimer’s disease in adults.

Leqembi was far from a cure, and made no claim to be one. Over 18 months, it had slowed the advance of the disease by an average of 27 percent, or by about five months, in a clinical trial of some ...

Leqembi — sold through a partnership between Eisai Co. and Cambridge-based Biogen — is one of the first medications approved that promises to slow the speed at which Alzheimer’s erases a ...

Leqembi is also approved and being marketed in the U.S., Japan, China, South Korea, Hong Kong, Israel, the United Arab Emirates, and Great Britain.

Biogen expects growth of its keenly watched Alzheimer's disease drug, Leqembi, to see a "linear trend" in the United States in the near term, a company executive said at a healthcare conference on ...

While Leqembi sales performed well outside the U.S. and Skyclarys. On Wednesday, Biogen Inc (NASDAQ:BIIB) reported fourth-quarter adjusted EPS of $3.44, up 17%, beating the consensus of $3.35.

Patients who started Leqembi early continued to benefit from the drug over three years, showing a slower rate of cognitive decline compared to the other two groups, according to an Eisai presentation.

Leqembi, an Alzheimer's drug from Biogen and Eisai, could give patients at the earliest stages of the disease more time to live normally and independent of others.